Immune Response Under Immunotherapy in Metastatic NSCLC: Sputum, Blood Samples and Microbioata Study
Prospective pathophysiological exploratory monocentric study, focusing on adult patients with non-small cell lung cancer (NSCLC) : non-squamous type without oncogenic addiction, metastatic, treated with immune checkpoint inhibitors alone or in combination with chemotherapy in front line at the CHRU de Tours, France.
Checked against the public recordLast updated Jan 17, 2024 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- University Hospital, Tours
- Interventions being studied
- Other: Blood; Other: sputum; Other: saliva; Other: stool
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Age of 18 years or over * Diagnosis of metastatic NSCLC (Stage IV) adenocarcinoma only * Absence of oncogenic addiction (EGFR, ALK, ROS1, RET, MET, BRAF) * Treatment with ICI anti-PD1 or anti-PDL1 (pembrolizumab or atezolizumab) as 1st line treatment alone or in combination with chemotherapy and/or anti-angiogenic (bevacizumab). * 1st injection of ICI, whether or not combined with chemotherapy Exclusion Criteria: * Patient under judicial protection * Pregnant or breastfeeding women * NSCLC of the epidermal or undifferentiated type * Opposition to data processing
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Ferreira MarionLos Angeles, California
- University hospitalTours
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 17, 2024. Always confirm current availability with the study team.